NCT01954576 is a NA clinical trial of NovoTTF-100A in Glioblastoma, sponsored by University of Florida.

Who is sponsoring NCT01954576?

NCT01954576 is sponsored by University of Florida.

What drugs are being tested in NCT01954576?

Interventions in NCT01954576: NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis.

What condition does NCT01954576 study?

NCT01954576 studies Glioblastoma, Brain Neoplasms.

Is NCT01954576 still recruiting?

NCT01954576 is currently terminated. Last updated 31 October 2022.

Last reviewed 2022-10-31 · How we verify

NCT01954576

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme

Terminated NA Last updated 31 October 2022

What this trial tests

NA trial testing NovoTTF-100A in Glioblastoma in 21 participants. Terminated before completion.

Timeline

10 October 2013

Primary endpoint
14 May 2021

14 May 2021

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	10 October 2013
Primary completion	14 May 2021
Estimated completion	14 May 2021
Sites	2 locations across United States

Drugs / interventions tested

NovoTTF-100A
Quality-of-life assessment
Laboratory biomarker analysis — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Brain Neoplasms — all drugs for Brain Neoplasms →

Sponsor

University of Florida

Who can join

22 and older, any sex, with Glioblastoma or Brain Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme. NovoTTF therapy uses a low intensity electric current to kill tumor cells. NovoTTF therapy may be effective treatment for brain cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor treating fields: a novel treatment modality and its use in brain tumors.
Hottinger AF, Pacheco P, Stupp R. · · 2016 · cited 132× · PMID 27664860 · DOI 10.1093/neuonc/now182
Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Ghiaseddin AP, Shin D, Melnick K, Tran DD. · · 2020 · cited 79× · PMID 32734509 · DOI 10.1007/s11864-020-00773-5
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future.
Guo X, Yang X, Wu J, Yang H, et al · · 2022 · cited 39× · PMID 35954334 · DOI 10.3390/cancers14153669
Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging.
Soni VS, Yanagihara TK. · · 2019 · cited 11× · PMID 31783910 · DOI 10.1186/s40644-019-0259-8
PATH-29. CLINICAL SIGNIFICANCE OF TEMOZOLOMIDE-INDUCED SOMATIC HYPERMUTATION IN INITIALLY LOW-GRADE IDH-MUTANT DIFFUSE GLIOMAS
Yu Y, Hilz S, Grimmer M, Solomon D, et al · · 2018
PATH-28. THE NATURAL HISTORY OF BRAF V600E-MUTATED GLIOBLASTOMAS IN ADULTS
Schreck K, Vera E, Aboud O, Acquaye A, et al · · 2018
PATH-27. IDENTIFYING THE GENETIC SIGNATURE OF RESPONSE IN A PHASE II STUDY OF TUMOR TREATING FIELDS IN RECURRENT GLIOBLASTOMA
Tran D, Warren S, Friedman W, Ghiaseddin A, et al · · 2018
PATH-26. NEURO-ONCOLOGY NEXT-GENERATION SEQUENCING 219-GENE PANEL FOR COMPREHENSIVE CLINICAL TESTING
Ida C, Barr Fritcher E, Zysk C, Voss J, et al · · 2018

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01954576 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 31 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01954576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing